<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36918938</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2523-3106</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Advances in rheumatology (London, England)</Title><ISOAbbreviation>Adv Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Prevalence of Sj&#xf6;gren's syndrome according&#xa0;to 2016 ACR-EULAR classification criteria in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>11</StartPage><MedlinePgn>11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s42358-022-00280-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Diagnosis of SS is a complex task, as no symptom or test is unique to this syndrome. The American-European Consensus Group (AECG 2002) and the American-European classification criteria of 2016 (ACR/EULAR 2016) emerged through a search for consensus. This study aims to assess the prevalence of Sj&#xf6;gren's Syndrome (SS) in patients with Systemic Lupus Erythematosus (SLE), according to AECG 2002 and ACR-EULAR 2016 classifications, as well as clinical and histopathological features in this overlap. To date, there is no study that has evaluated SS in SLE, using the two current criteria.</AbstractText><AbstractText Label="METHODS">This cross-sectional study evaluated 237 SLE patients at the outpatient rheumatology clinic between 2016 and 2018. Patients were submitted to a dryness questionnaire, whole unstimulated salivary flow (WUSF), "Ocular Staining Score" (OSS), Schirmer's test I (ST-I), and labial salivary gland biopsy (LSGB).</AbstractText><AbstractText Label="RESULTS">After verifying inclusion and exclusion criteria, a total of 117 patients were evaluated, with predominance of females (94%) and mixed ethnicity (49.6%). The prevalence of SS was 23% according to AECG 2002 and 35% to ACR-EULAR 2016. Kappa agreement between AECG 2002 and ACR-EULAR 2016 were 0.7 (p&#x2009;&lt;&#x2009;0.0001). After logistic regression, predictors for SS were: anti/Ro (OR&#x2009;=&#x2009;17.86, p&#x2009;&lt;&#x2009;0.05), focal lymphocytic sialadenitis (OR&#x2009;=&#x2009;3.69, p&#x2009;&lt;&#x2009;0.05), OSS&#x2009;&#x2265;&#x2009;5 (OR&#x2009;=&#x2009;7.50, p&#x2009;&lt;&#x2009;0.05), ST I positive (OR&#x2009;=&#x2009;2.67, p&#x2009;&lt;&#x2009;0.05), and WUSF&#x2009;&#x2264;&#x2009;0.1&#xa0;mL/min (OR&#x2009;=&#x2009;4.13, p&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION">The prevalence of SS in SLE was 23% (AECG 2002) and 35% (ACR-EULAR 2016). The presence of glandular dysfunction, focal lymphocytic sialadenitis, and anti/Ro were predictors of SS in SLE. The greatest advantage of the new ACR-EULAR 2016 criteria is to enable an early diagnosis and identify the overlapping of these two diseases. ACR-EULAR&#xa0;2016 criteria is not yet validated for secondary SS and this study is a pioneer in investigating prevalence based on the new criteria.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gianordoli</LastName><ForeName>Ana Paula Esp&#xed;ndula</ForeName><Initials>APE</Initials><AffiliationInfo><Affiliation>Rheumatology Division, University Hospital Cassiano Ant&#xf4;nio Moraes of Federal University of Esp&#xed;rito Santo (HUCAM-UFES/EBSERH), Mal. Campos Avenue, n&#xb0; 1355, Santos Dumont, Vit&#xf3;ria, ES, 29041-295, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laguardia</LastName><ForeName>Rafaella Vila Real Barbosa</ForeName><Initials>RVRB</Initials><AffiliationInfo><Affiliation>Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Maria Carmen F S</ForeName><Initials>MCFS</Initials><AffiliationInfo><Affiliation>Pathology Department, Science Health Centre, University Hospital (HUCAM-UFES/EBSERH), Federal University of Espirito Santo, Vit&#xf3;ria, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorge</LastName><ForeName>Fabiano Cade</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva Salom&#xe3;o</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caser</LastName><ForeName>Larissa Carvalho</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moulaz</LastName><ForeName>Isac Ribeiro</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>&#xc9;rica Vieira</ForeName><Initials>&#xc9;V</Initials><AffiliationInfo><Affiliation>Rheumatology Division, University Hospital Cassiano Ant&#xf4;nio Moraes of Federal University of Esp&#xed;rito Santo (HUCAM-UFES/EBSERH), Mal. Campos Avenue, n&#xb0; 1355, Santos Dumont, Vit&#xf3;ria, ES, 29041-295, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Samira Tatiyama</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Physiotherapy, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Ketty Lysie Libardi Lira</ForeName><Initials>KLLL</Initials><AffiliationInfo><Affiliation>Rheumatology Division, University Hospital Cassiano Ant&#xf4;nio Moraes of Federal University of Esp&#xed;rito Santo (HUCAM-UFES/EBSERH), Mal. Campos Avenue, n&#xb0; 1355, Santos Dumont, Vit&#xf3;ria, ES, 29041-295, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valim</LastName><ForeName>Val&#xe9;ria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0625-1308</Identifier><AffiliationInfo><Affiliation>Rheumatology Division, University Hospital Cassiano Ant&#xf4;nio Moraes of Federal University of Esp&#xed;rito Santo (HUCAM-UFES/EBSERH), Mal. Campos Avenue, n&#xb0; 1355, Santos Dumont, Vit&#xf3;ria, ES, 29041-295, Brazil. val.valim@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Adv Rheumatol</MedlineTA><NlmUniqueID>101734172</NlmUniqueID><ISSNLinking>2523-3106</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012793" MajorTopicYN="Y">Sialadenitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012469" MajorTopicYN="N">Salivary Glands</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACR-EULAR 2016</Keyword><Keyword MajorTopicYN="N">Classification criteria</Keyword><Keyword MajorTopicYN="N">Labial salivary gland biopsy</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">Sj&#xf6;gren's syndrome</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>1</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36918938</ArticleId><ArticleId IdType="doi">10.1186/s42358-022-00280-1</ArticleId><ArticleId IdType="pii">10.1186/s42358-022-00280-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pan HF, Ye DQ, Wang Q, Li WX, Zhang N, Li XP, Xu JH, Dai H. Clinical and laboratory profiles of systemic lupus erythematosus associated with Sj&#xf6;gren syndrome in China: a study of 542 patients. Clin Rheumatol. 2008;27:339&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-007-0720-0</ArticleId><ArticleId IdType="pubmed">17899309</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton JM. Sj&#xf6;gren&#x2019;s syndrome and systemic lupus erythematosus. Br Med J. 1959;21(1):466&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.1.5120.466</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Catoggio LJ, Cardiel MH, Bonfa E, Caeiro F, Sato E, Massardo L, Molina-Restrepo JF, Toledano MG, Barile-Fabris LA, Amigo MC, Acevedo-V&#xe1;squez EM, Abadi I, Wojdyla D, Alarc&#xf3;n-Riquelme ME, Alarc&#xf3;n GS, Pons-Estel BA. GLADEL. Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus. 2015;24:536&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314567753</ArticleId><ArticleId IdType="pubmed">25697768</ArticleId></ArticleIdList></Reference><Reference><Citation>Rus V, Maury EE, Hochberg MC. The epidemiology of systemic lupus erythematosus. Dubois lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams &amp; Wilkins; 2007.</Citation></Reference><Reference><Citation>Borba EF, et al. Systemic lupus erythematosus consensus. Braz J Rheumatol. 2008;48(4):196&#x2013;207 (in Portuguese).</Citation></Reference><Reference><Citation>Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol. 1990;29:185&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/29.3.185</ArticleId><ArticleId IdType="pubmed">2357500</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, Farewell V, Gordon C. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015;54:836&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu412</ArticleId><ArticleId IdType="pubmed">25323056</ArticleId></ArticleIdList></Reference><Reference><Citation>Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C, EULAR Sj&#xf6;gren's Task Force. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69(6):1103&#x2013;9. https://doi.org/10.1136/ard.2009.110619 . Erratum in: Ann Rheum Dis. 2011;70:880.</Citation></Reference><Reference><Citation>Valim V, et al. Prevalence of primary Sj&#xf6;gren syndrome in an important metropolitan area in Brazil. Braz J Rheumatol. 2013;53(1):29&#x2013;34 (in Portuguese).</Citation></Reference><Reference><Citation>Gilboe IM, Kvien TK, Uhlig T, Husby G. Sicca symptoms and secondary Sj&#xf6;gren&#x2019;s syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables. Ann Rheum Dis. 2001;60:1103&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.60.12.1103</ArticleId><ArticleId IdType="pubmed">11709451</ArticleId><ArticleId IdType="pmc">1753445</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasoto SG, Adriano de Oliveira Martins V, Bonfa E. Sj&#xf6;gren&#x2019;s syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol. 2019;11:33&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S167783</ArticleId><ArticleId IdType="pubmed">30774485</ArticleId><ArticleId IdType="pmc">6357904</ArticleId></ArticleIdList></Reference><Reference><Citation>Alani H, Henty JR, Thompson NL, Jury E, Ciurtin C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sj&#xf6;gren&#x2019;s syndrome (secondary Sj&#xf6;gren&#x2019;s syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol. 2018;47:141&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2017.1324909</ArticleId><ArticleId IdType="pubmed">28927315</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal R, Anaya JM, Koelsch KA, Kurien BT, Scofield RH. Association between secondary and primary Sj&#xf6;gren&#x2019;s syndrome in a large collection of lupus families. Autoimmune Dis. 2015;2015:298506.</Citation><ArticleIdList><ArticleId IdType="pubmed">26246904</ArticleId><ArticleId IdType="pmc">4515287</ArticleId></ArticleIdList></Reference><Reference><Citation>Andonopoulos AP, Skopouli FN, Dimou GS, Drosos AA, Moutsopoulos HM. Sj&#xf6;gren&#x2019;s syndrome in systemic lupus erythematosus. J Rheumatol. 1990;17:201&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2319519</ArticleId></ArticleIdList></Reference><Reference><Citation>Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, Moutsopoulos HM. Sj&#xf6;gren&#x2019;s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sj&#xf6;gren&#x2019;s syndrome. Arthritis Rheum. 2004;50:882&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20093</ArticleId><ArticleId IdType="pubmed">15022331</ArticleId></ArticleIdList></Reference><Reference><Citation>Baer AN, Maynard JW, Shaikh F, Magder LS, Petri M. Secondary Sjogren&#x2019;s syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol. 2010;37:1143&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.090804</ArticleId><ArticleId IdType="pubmed">20360189</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Q, Altman RD, Wang X. Systemic lupus erythematosus with Sj&#xf6;gren syndrome compared to systemic lupus erythematosus alone: a meta-analysis. J Clin Rheumatol. 2012;18:28&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0b013e31823ecbdf</ArticleId><ArticleId IdType="pubmed">22157271</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X, International Sj&#xf6;gren&#x2019;s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sj&#xf6;gren&#x2019;s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-210571</ArticleId><ArticleId IdType="pubmed">27789466</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitcher JP, Shiboski CH, Shiboski SC, Heidenreich AM, Kitagawa K, Zhang S, Hamann S, Larkin G, McNamara NA, Greenspan JS, Daniels TE, Sj&#xf6;gren&#x2019;s International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj&#xf6;gren&#x2019;s Syndrome International Registry. Am J Ophthalmol. 2010;149:405&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2009.09.013</ArticleId><ArticleId IdType="pubmed">20035924</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovelli RA. Retrospective histological analysis of minor salivary gland in patients with dry syndrome. Master&#x2019;s thesis, Federal University of Esp&#xed;rito Santo; 2013 (in Portuguese).</Citation></Reference><Reference><Citation>Le Goff M, Cornec D, Jousse-Joulin S, Guellec D, Costa S, Marhadour T, Le Berre R, Genestet S, Cochener B, Boisrame-Gastrin S, Renaudineau Y, Pers JO, Saraux A, Devauchelle-Pensec V. Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sj&#xf6;gren&#x2019;s syndrome. Arthritis Res Ther. 2017;6(19):269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1475-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Grennan DM, Ferguson M, Ghobarey AE, Williamson J, Dick WC, Buchanan WW. Sjogren&#x2019;s syndrome in SLE: Part 2. An examination of the clinical significance of Sjogren&#x2019;s syndrome by comparison of its frequency in typical and atypical forms of SLE, overlap syndromes and scleroderma. N Z Med J. 1977;86:376&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">272547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Garc&#xed;a-Carrasco M, Font J, Ramos M, Reverter JC, Mu&#xf1;oz FJ, Miret C, Espinosa G, Ingelmo M. Antiphospholipid antibodies in primary Sj&#xf6;gren&#x2019;s syndrome: prevalence and clinical significance in a series of 80 patients. Clin Exp Rheumatol. 1997;15:361&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9272295</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte T, Hartung K, Sachse C, Matthias T, Fricke M, Kalden JR, Lakomek HJ, Peter HH, Schmidt RE. Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group. Rheumatol Int. 2000;19:107&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002960050112</ArticleId><ArticleId IdType="pubmed">10776689</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Kang SG. Recurrent annular erythema in Sj&#xf6;gren&#x2019;s/lupus erythematosus overlap syndrome: an additional case from Korea. J Dermatol. 1996;23:431&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1346-8138.1996.tb04049.x</ArticleId><ArticleId IdType="pubmed">8708160</ArticleId></ArticleIdList></Reference><Reference><Citation>Sz&#xe1;nt&#xf3; A, Kiss E, Sas A, Szegedi G, Zeher M. Association of systemic lupus erythematosus and Sj&#xf6;gren&#x2019;s syndrome. Orv Hetil. 2005;11(146):2533&#x2013;8 (in Hungarian).</Citation></Reference><Reference><Citation>Xu D, et al. Patients with Sj&#xf6;gren&#x2019;s syndrome-onset lupus have distinct clinical manifestations and a benign prognosis: a case-control study. Lupus. 2010;19:197&#x2013;200 (in Portuguese).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309348235</ArticleId><ArticleId IdType="pubmed">19900977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghillani P, Andr&#xe9; C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, Goulvestre C, Gleizes A, Dragon-Durey MA, Alyanakian MA, Chretien P, Chollet-Martin S, Musset L, Weill B, Johanet C. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev. 2011;10:509&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.03.004</ArticleId><ArticleId IdType="pubmed">21447407</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimasu T, Hiroi A, Ohtani T, Uede K, Furukawa F. Comparison of anti 60 and 52 kDa SS-A/Ro antibodies in the pathogenesis of cutaneous lupus erythematosus. J Dermatol Sci. 2002;29:35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0923-1811(02)00004-X</ArticleId><ArticleId IdType="pubmed">12007719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bologna SB, Cavalcante WS, Florezi GP, Souza MM, Nico MMS, Louren&#xe7;o SV. Distinct salivary gland features in Sj&#xf6;gren&#x2019;s syndrome and lupus erythematosus sialadenite. Am J Dermatopathol. 2020;42:407&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/DAD.0000000000001535</ArticleId><ArticleId IdType="pubmed">31592858</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>